Printer Friendly

ONCOR CONCLUDES PUBLIC OFFERING

 ONCOR CONCLUDES PUBLIC OFFERING
 GAITHERSBURG, Md., Feb. 7 /PRNewswire/ -- Oncor, Inc.


(NASDAQ: ONCR), today announced that it has completed a public offering of 3,450,000 common shares, including the underwriters 100 percent exercise of its over-allotment option of 450,000 shares, at a price to the public of $10.50 per share with total net proceeds to Oncor of approximately $33,706,500, before deducting estimated offering expenses.
 Smith Barney, Harris Upham & Co. Incorporated and Vector Securities International Inc. are the representatives of the several underwriters that offered the shares to the public.
 Proceeds from the sale of the shares by Oncor are expected to be used for product research and development, capital expenditures, sales and marketing and general corporate and working capital purposes.
 Oncor develops, manufactures and markets DNA probe test systems and related products for use in the diagnosis, monitoring and management of cancer and other genetic diseases.
 -0- 2/7/92
 /CONTACT: Stephen Turner chairman & CEO of Oncor, Inc., 301-963-3500/
 (ONCR) CO: Oncor, Inc. ST: Maryland IN: MTC SU: OFR


SB-KW -- NY069 -- 7900 02/07/92 15:59 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 7, 1992
Words:183
Previous Article:GUILTY PLEA IN PUERTO RICO HIJACKING CASE
Next Article:MITSUBISHI MOTORS NAMES LEPLEY SENIOR VICE PRESIDENT/SALES AND MARKETING AS COMPANY ANNOUNCES NEW REORGANIZATIONAL STRUCTURE
Topics:


Related Articles
ONCOR COMMENCES PUBLIC OFFERING
ONCOR REPORTS RECORD SALES FOR FOURTH QUARTER AND FULL YEAR 1992
ONCOR ACQUIRES EXCLUSIVE LICENSES FOR DNA PROBES TO DETECT THE TELOMERES OF HUMAN CHROMOSOMES
ONCOR REPORTS RECORD SALES FOR SECOND QUARTER AND SIX MONTHS OF 1993
ONCOR, INC. FILES REGISTRATION STATEMENT FOR OFFERING OF 3,000,000 SHARES OF COMMON STOCK
ONCOR, INC. COMMENCES PUBLIC OFFERING
ONCOR, INC. ANNOUNCES UNDERWRITERS' EXERCISE OF OVER-ALLOTMENT
ONCOR, INC.'S SUBSIDIARY, ONCORMED, INC., COMMENCES INITIAL PUBLIC OFFERING
ONCOR SUBMITS FDA APPLICATION FOR CHRONIC MYELOGENOUS LEUKEMIA GENETIC TEST SYSTEM
CECIL KOST APPOINTED PRESIDENT AND CHIEF OPERATING OFFICER OF ONCOR, INC.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters